Pembrolizumab (Keytruda) for the further treatment of advanced melanoma
In 2015, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) wanted to find out whether pembrolizumab (trade name: Keytruda) has any advantages or disadvantages when compared with the standard treatments for people with advanced melanoma who have had unsuccessful treatment. The standard treatment depends on things like which drug was used before and is individually tailored by the doctor.
To answer the research question, the researchers analyzed the data from one study. One group of participants (91 people) received pembrolizumab, while another group (97 people) received ipilimumab. For people who have had treatment before and who have the option of receiving ipilimumab, the study provided relevant results. These results are described below.
The study didn't provide suitable data for people who don't have the option of using ipilimumab. So it remains unclear whether pembrolizumab has any advantages or disadvantages for these people.